Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915013 · ClinicalTrials.gov registry record · Phase 1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
A Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05915013: Recruiting Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major, sponsored by Yale University.
NCT05915013 is a Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05915013, a Phase 1 study of Post Traumatic Stress Disorder and Depressive Disorder, Major, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Primary Outcome
This outcome will be assessed via functional magnetic resonance imaging (fMRI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Perampanel
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-07 |
| Est. Completion | 2032-12 |
| Phase | Phase 1 |
What NCT05915013 shows while recruiting
NCT05915013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05915013 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05915013 about?
NCT05915013 is a clinical study titled "Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response". The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid recepto...
What is the current status of trial NCT05915013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-07. Estimated completion is 2032-12.
What conditions does trial NCT05915013 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Depressive Disorder, Major.
What interventions are being tested in trial NCT05915013?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Perampanel (DRUG).
Who is sponsoring clinical trial NCT05915013?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05915013 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05915013's enrollment target sits among peer trials
50 176th of 262 higher than 83 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
RECRUITING · Phase 1
-
Mitigating PTSD-CUD After Sexual Assault
RECRUITING · Phase 1
-
A Study of Psilocybin for PTSD
ACTIVE NOT RECRUITING · Phase 1
-
Biological Signatures, Probiotic Among Those With mTBI and PTSD
COMPLETED · Phase 1
-
Cannabidiol as a Treatment for AUD Comorbid With PTSD
COMPLETED · Phase 1
-
Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI